STOCK TITAN

Assembly Biosciences Inc - ASMB STOCK NEWS

Welcome to our dedicated news page for Assembly Biosciences (Ticker: ASMB), a resource for investors and traders seeking the latest updates and insights on Assembly Biosciences.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Assembly Biosciences's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Assembly Biosciences's position in the market.

Rhea-AI Summary
Assembly Biosciences to present new data on hepatitis B and hepatitis D pipeline programs at the 2023 International HBV Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.19%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.94%
Tags
-
Rhea-AI Summary
Assembly Biosciences, Inc. (Nasdaq: ASMB) announced preclinical data on ABI-5366, a long-acting herpes simplex virus (HSV) helicase inhibitor for high-recurrence genital herpes. The data showed potent antiviral activity against both HSV-1 and HSV-2, sustained plasma concentrations, and a favorable safety profile. The company plans to enter the clinic in the first half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.63%
Tags
none
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.67%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.91%
Tags
conferences
-
Rhea-AI Summary
Assembly Biosciences, Inc. will present in a fireside chat during the 2023 Jefferies Healthcare Conference on June 7, 2023. The presentation will be given by the CEO and CSO and will be available via live webcast and replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.67%
Tags
conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.96%
Tags
-
-
Assembly Biosciences Inc

Nasdaq:ASMB

ASMB Rankings

ASMB Stock Data

79.61M
3.63M
32.97%
13.15%
0.78%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States
South San Francisco

About ASMB

assembly biosciences, inc. (nasdaq: asmb) is a public clinical-stage biotechnology company advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and novel oral live biotherapeutics for disorders associated with the microbiome. assembly is developing two innovative platform programs: an hbv program advancing a new class of oral therapeutics for the treatment of hepatitis b virus (hbv) infection and a microbiome program developing novel oral live biotherapeutics designed to address diseases associated with the microbiome. assembly’s hbv program is advancing multiple drug candidates with the aim of increasing cure rates in patients with chronic hbv. the company's microbiome program consists of a fully integrated platform that includes a robust strain identification and selection process, methods for strain isolation and growth under current good manufacturing practices and a patent-pending delivery system, gemicel®, which allows for targeted ora